Robert C. Ash

TL;DR: The National Marrow Donor Program has benefited a substantial number of patients in need of marrow transplants from closely HLA-matched unrelated donors and has facilitated the recruitment of unrelated donors into the donor pool and the access to suitable marrow.

TL;DR: Among recipients of T-cell-depleted transplants for early leukemia, radiation doses greater than or equal to 11 Gy, dose rates greater than 14 cGy/min, and additional posttransplant immune suppression with cyclosporine alone or methotrexate were associated with fewer treatment failures but use of monoclonal antibodies rather than physical techniques for T- cell depletion and fractionated radiation was associated with increased treatment failure and lower leukemia-free survival.

TL;DR: In early leukemia, alternative donor transplants have a more than twofold increased risk of treatment failure compared with HLA-identical sibling transplants, but this difference is less in advanced leukemia.

TL;DR: It is demonstrated that leukocyte infusions that administered a defined T-cell dose can exert a profound graft-versus- leukemia effect and are an effective form of salvage immunotherapy in allogeneic marrow transplant recipients.

TL;DR: Bone marrow transplants are effective therapy for Fanconi anemia and the adverse impact of increasing age and lower pretransplant platelet count on transplant outcome favors earlier intervention, especially when there is an HLA-identical sibling donor.